DRG publishes a new primary market research report tracking awareness, trial, and use of Mylan’s Wixela Inhub, a therapeutic equivalent to Advair.
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two…
The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz) for the moderate to severe population,…
The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives…
In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb) biosimilars launched in the United States. Between mid-…
MARKET OUTLOOKNon-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants further shift the complicated treatment algorithm…
Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven emerging pharmaceutical markets (Brazil, Russia, India, China,…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, and Peru). We report…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Asia-Pacific (Hong Kong, Philippines, Taiwan, Thailand, Vietnam,…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven major mature pharmaceutical markets (the United States, France…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Middle East and Africa (Egypt, Nigeria, Saudi Arabia, and South…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium, Czech…